Los Angeles – September 10, 2026 -- Schall, Brown & Schwartz LLP (SBS) has issued a reminder to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a securities class action lawsuit alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lead plaintiff deadline is set for September 28, 2026.
Lawsuit covers CAPR shares purchased between December 17, 2025 and July 26, 2026
The class action targets investors who purchased Capricor shares during this roughly seven-month window. Appointment as lead plaintiff is not a prerequisite for shareholders to participate in any eventual recovery.
Complaint alleges Capricor altered its Deramiocel statistical analysis plan without FDA sign-off
According to the complaint, Capricor changed the statistical analysis plan used to evaluate clinical data for its cell therapy candidate Deramiocel before resubmitting its Biologics License Application (BLA) to the FDA. The suit alleges the FDA had not agreed to these changes from the pre-specified plan prior to resubmission, exposing the Company to a substantial risk that regulators would reject the BLA for lack of sufficient evidence of effectiveness.
Investors claim Capricor's public statements were materially misleading throughout the class period
The complaint states that Capricor's disclosures to the market during the class period misrepresented the regulatory risk tied to the altered analysis plan. Shareholders allege they suffered financial damages once the underlying facts became known.
SBS is soliciting shareholders to consider lead plaintiff roles ahead of the September 28 deadline
Schall, Brown & Schwartz LLP is inviting CAPR shareholders who incurred losses during the class period to contact the firm to discuss their legal options. The class has not yet been certified, meaning shareholders who take no action remain unrepresented absent class members until that occurs.